Three-component formulation: The packaging lists CJC 3 mg, ipamorelin 3 mg, and tesamorelin 6 mg.

12 mg listed total: The labelled component quantities add up to 12 mg. This is not an individual dose.

2 mL pen presentation: Labelled as a multi-dose, pre-filled pen for single-patient use.

Pack contents: The packaging states that one pen and eight sterile, single-use injection needles are included.

Linked research background: The Research section provides publications on related individual compounds. These studies do not validate this specific product or combination.

Product-specific handling: Refer to verified manufacturer documentation for storage, handling, and intended use. Listed specifications reflect packaging information, not independent testing.

Anti-Aging: 0.60 mg daily in the evening (10 clicks)

General Wellness: 1.2 mg daily in the evening (20 clicks)

Body Recomposition: 1.5 mg daily in the evening (25 clicks)

Fat Loss Support: 1.80 mg daily in the evening (30 clicks)

What is the Noventra Pharma Growth Matrix 12 mg Research Pen?

This product is listed as Noventra Pharma Growth Matrix in a research pen format, with a stated quantity of 12 mg. Refer to the manufacturer’s documentation for the exact formulation and product specifications.

What does 12 mg mean?

12 mg is the quantity stated in the product name. It should not be interpreted as an individual dose, concentration, or instruction for use.

Which ingredients does Growth Matrix contain?

The Growth Matrix name alone does not identify its ingredients. Check the product label and manufacturer’s documentation for the verified composition before purchase.

Does research on an ingredient validate this specific pen?

No. Published research on an ingredient does not establish the identity, purity, stability, safety, or effectiveness of this specific branded product. Product-specific documentation should be reviewed separately.

How should the research pen be stored and handled?

Follow the storage and handling requirements on the product’s label and accompanying documentation. Do not assume that instructions for another pen apply. Contact the supplier if any instructions are missing or unclear.

Are dosing or administration instructions provided here?

No. This FAQ does not provide dosing, preparation, or administration instructions. The research pen designation does not establish suitability for human use or self-administration.

What should I do if the packaging is damaged or the label is unclear?

Do not use the product. Contact the supplier to clarify the label or resolve any packaging concerns before opening or handling it.

Growth Matrix — Research Background

The product packaging lists CJC 3 mg, ipamorelin 3 mg, and tesamorelin 6 mg. The publications below provide background on related individual compounds, not clinical validation of the Growth Matrix blend.

CJC-1295: Growth hormone and IGF-I signalling

Two short randomized, placebo-controlled trials in healthy adults examined the effects of long-acting CJC-1295 on growth hormone and IGF-I secretion. The packaging identifies only “CJC”, so equivalence to the CJC-1295 formulation studied cannot be assumed.

Read study: Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.

Ipamorelin: Preclinical research

This pharmacology study investigated ipamorelin’s effects on growth hormone release using rat pituitary cells and animal models. These preclinical findings do not establish benefits or safety in humans.

Read study: Ipamorelin, the first selective growth hormone secretagogue.

Tesamorelin: Body-composition research

A randomized, placebo-controlled trial in 60 abdominally obese adults with reduced growth hormone secretion examined tesamorelin’s effects on visceral fat and cardiovascular risk markers. Results apply to the population and formulation studied, not automatically to this combined research pen.

Read study: Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.

Important Research Context

These papers do not establish the identity, purity, sterility, stability, safety, or effectiveness of this specific branded product or its three-component combination. They do not validate anti-aging, wellness, muscle-growth, or fat-loss claims for Growth Matrix and should not be used as preparation, dosing, or administration instructions.